Evidence map›Paper›PMID 42613601›Full record

ArticleBMC cancer2026

Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer.

Sithumini Sarathchandra, Chiara Fittipaldi, Nanfizat Abiket Alamukii, Anikó Kovács, Toshima Z Parris

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sithumini Sarathchandra *Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Chiara Fittipaldi *Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Nanfizat Abiket AlamukiiDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anikó KovácsRegion Västra Götaland, Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Toshima Z ParrisDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. toshima.parris@oncology.gu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThree-dimensional (3D) cancer spheroids mimic key morphological and biological features of solid tumors, providing a valuable model for evaluating drug responses. Here, we investigated whether intrinsic cancer stem cell composition and tumor subtype determine spheroid formation capacity, transcriptional profiling, and therapeutic response in breast cancer cell lines.

methodsUsing the liquid overlay technique, we optimized conditions for reproducible spheroid generation using 10 human cancer cell lines derived from breast cancer, glioblastoma, and malignant melanoma. Spheroid morphology and growth dynamics were assessed over a 20-day period, while breast cancer stem cell abundance was evaluated in 2D monolayer cultures and 3D spheroids using immunohistochemistry and flow cytometry. RNA sequencing (RNA-seq) transcriptomic profiling and drug responses to bortezomib+nedaplatin following 24- and 72-hour exposure were compared between both culture systems.

resultsOptimized conditions yielded compact spheroids (5/10 cell lines), loose aggregates (3/10), and no spheroid formation (2/10). Compact spheroids (mean ± SEM, 576 ± 18 μm) and those derived from triple-negative breast cancers (TNBCs; 550 ± 19 μm) were significantly smaller than loose aggregates (822 ± 36 μm) and non-TNBC-derived spheroids (934 ± 41 μm), respectively. RNA-seq demonstrated that transcriptional variation was primarily driven by intrinsic differences between cell lines rather than culture conditions. However, spheroid-forming cells induced distinct gene expression patterns enriched in extracellular matrix remodeling, developmental pathways, and stemness-related genes. In total, 1478 differentially expressed genes were associated with spheroid formation. TENM4 (Teneurin Transmembrane Protein 4) was the only consistently deregulated gene in both spheroid-forming breast cancer models, showing up to 4.9-fold and 2.6-fold higher expression in HCC1806 and BT-474 spheroids, respectively. Consistent with the transcriptomic findings, immunohistochemical analysis demonstrated increased TENM4 protein expression, predominantly localized to the spheroid cores. Drug screening further demonstrated increased chemoresistance in 3D spheroids, with up to 7.5-fold higher viability in TNBC spheroids following bortezomib+nedaplatin treatment.

conclusionsTaken together, these findings highlight molecular and cellular determinants of spheroid formation in breast cancer cell lines, including stemness-associated features and upregulation of TENM4. Our results further demonstrate that intrinsic tumor subtype shapes spheroid morphology, transcriptional profiles, and drug response, providing novel insight into the mechanisms underlying 3D growth and chemoresistance that may help inform future therapeutic strategies.

Indexed as

Antineoplastic AgentsNeoplastic Stem CellsSpheroids, CellularTriple Negative Breast NeoplasmsBortezomibCell Line, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsBortezomib2D monolayers3D spheroidsBreast cancer stem cellsRNA sequencingTherapeutic vulnerabilityTranscriptomic profiling

Identifiers

PMID42613601
PMCPMC13483856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.